{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T08:08:07Z","timestamp":1784448487733,"version":"3.55.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Cetuximab sarotalocan, which utilizes the light-activatable dye IRDye700Dx conjugated with cetuximab, is a first-in-class drug based on photoimmunotherapy for treating recurrent head and neck squamous cell carcinoma. Cetuximab frequently induces hypomagnesemia and secondary hypocalcemia. Herein, we report a case of independent hypocalcemia without hypomagnesemia during treatment and discuss symptom progression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case Presentation<\/jats:title>\n            <jats:p>A female patient with left epipharyngeal cancer, hypothyroidism, and hypoparathyroidism was treated with cetuximab and sarotalocan. On day 3, serum-adjusted calcium levels decreased from 9.6 to 7.4\u00a0mg\/dL, increased to 8.2\u00a0mg\/dL on day 9, and further increased to 8.8\u00a0mg\/dL on day 27; serum magnesium levels were not evaluated. After the second administration, serum-adjusted calcium levels decreased two days later, fluctuating between 7.6 and 8.1\u00a0mg\/dL for three weeks. Serum magnesium levels were within the normal range, with no significant variation detected during the second cycle. A similar symptom course was observed during the third cycle. The patient received enteral nutrition daily with 424.8\u20131,038.4\u00a0mg of calcium, with daily adjustment during the administration, except on day 2. She received peripheral intravenous nutrition for several days after tumor illumination. Concomitant medications did not appear to affect serum calcium levels. Considering the case process and previous reports, we hypothesized that concomitant hypoparathyroidism, in addition to reduced calcium intake due to the treatment, may have contributed to the observed reduction.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Hypocalcemia without hypomagnesemia can occur in patients with hypoparathyroidism receiving near-infrared photoimmunotherapy with cetuximab sarotalocan. The precise mechanisms and epidemiological features warrant further investigations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40780-025-00465-y","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T21:13:39Z","timestamp":1751663619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Temporary hypocalcemia induced by cetuximab sarotalocan without hypomagnesemia in a patient with hypoparathyroidism: a novel case report"],"prefix":"10.1186","volume":"11","author":[{"given":"Moeko","family":"Kado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiko","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayoshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"465_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1056\/NEJMra1715715","volume":"382","author":"LQM Chow","year":"2020","unstructured":"Chow LQM. Head and neck cancer. N Engl J Med. 2020;382:60\u201372. https:\/\/doi.org\/10.1056\/NEJMra1715715.","journal-title":"N Engl J Med"},{"key":"465_CR2","doi-asserted-by":"publisher","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492. Epub 2018 Sep 12.\u00a0Erratum in: CA Cancer J Clin. 2020;70:313. https:\/\/doi.org\/10.3322\/caac.21609.","DOI":"10.3322\/caac.21492"},{"key":"465_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev.pathol.4.110807.092158","volume":"4","author":"SI Pai","year":"2009","unstructured":"Pai SI, Westra WH. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol. 2009;4:49\u201370. https:\/\/doi.org\/10.1146\/annurev.pathol.4.110807.092158.","journal-title":"Annu Rev Pathol"},{"key":"465_CR4","doi-asserted-by":"publisher","first-page":"5723","DOI":"10.1002\/cncr.24595","volume":"115","author":"ME Zafereo","year":"2009","unstructured":"Zafereo ME, Hanasono MM, Rosenthal DI, Sturgis EM, Lewin JS, Roberts DB, et al. The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx. Cancer. 2009;115:5723\u201333. https:\/\/doi.org\/10.1002\/cncr.24595.","journal-title":"Cancer"},{"key":"465_CR5","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.3390\/cancers15215117","volume":"15","author":"NL Miyazaki","year":"2023","unstructured":"Miyazaki NL, Furusawa A, Choyke PL, Kobayashi H. Review of RM-1929 near-infrared photoimmunotherapy clinical efficacy for unresectable and\/or recurrent head and neck squamous cell carcinoma. Cancers (Basel). 2023;15:5117. https:\/\/doi.org\/10.3390\/cancers15215117.","journal-title":"Cancers (Basel)"},{"key":"465_CR6","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1002\/hed.26885","volume":"43","author":"DM Cognetti","year":"2021","unstructured":"Cognetti DM, Johnson JM, Curry JM, Kochuparambil ST, McDonald D, Mott F, et al. Phase 1\/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma. Head Neck. 2021;43:3875\u201387. https:\/\/doi.org\/10.1002\/hed.26885.","journal-title":"Head Neck"},{"key":"465_CR7","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1007\/s10147-021-01960-6","volume":"26","author":"M Tahara","year":"2021","unstructured":"Tahara M, Okano S, Enokida T, Ueda Y, Fujisawa T, Shinozaki T, et al. A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma. Int J Clin Oncol. 2021;26:1812\u201321. https:\/\/doi.org\/10.1007\/s10147-021-01960-6.","journal-title":"Int J Clin Oncol"},{"key":"465_CR8","doi-asserted-by":"publisher","first-page":"e112558","DOI":"10.1371\/journal.pone.0112558","volume":"9","author":"CH Park","year":"2014","unstructured":"Park CH, Kim EH, Roh YH, Roh YH, Kim HY, Lee SK. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis. PLoS ONE. 2014;9:e112558.","journal-title":"PLoS ONE"},{"key":"465_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3892\/etm_00000047","volume":"1","author":"P Maliakal","year":"2010","unstructured":"Maliakal P, Ledford A. Electrolyte and protein imbalance following anti-EGFR therapy in cancer patients: A comparative study. Exp Ther Med. 2010;1:307\u201311. https:\/\/doi.org\/10.3892\/etm_00000047.","journal-title":"Exp Ther Med"},{"key":"465_CR10","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1007\/s13277-014-2983-9","volume":"36","author":"Q Wang","year":"2015","unstructured":"Wang Q, Qi Y, Zhang D, Gong C, Yao A, Xiao Y, et al. Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials. Tumour Biol. 2015;36:3471\u201382. https:\/\/doi.org\/10.1007\/s13277-014-2983-9.","journal-title":"Tumour Biol"},{"issue":"18","key":"465_CR11","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.3390\/cancers14184413","volume":"14","author":"I Okamoto","year":"2022","unstructured":"Okamoto I, Okada T, Tokashiki K, Tsukahara K. Quality-of-life evaluation of patients with unresectable locally advanced or locally recurrent head and neck carcinoma treated with head and neck photoimmunotherapy. Cancers (Basel). 2022;14(18):4413. https:\/\/doi.org\/10.3390\/cancers14184413.","journal-title":"Cancers (Basel)"},{"issue":"Suppl 1","key":"465_CR12","doi-asserted-by":"publisher","first-page":"bvad114.516","DOI":"10.1210\/jendso\/bvad114.516","volume":"7","author":"M Thomas","year":"2023","unstructured":"Thomas M, Janakiram N, Leary J, Foster-Schubert KE, Rao Narla R. SAT219 Severe isolated hypocalcemia with cetuximab & irinotecan chemotherapy. J Endocr Soc. 2023;7(Suppl 1):bvad114.516. https:\/\/doi.org\/10.1210\/jendso\/bvad114.516.","journal-title":"J Endocr Soc."},{"key":"465_CR13","doi-asserted-by":"publisher","first-page":"e789","DOI":"10.1097\/CAD.0000000000001212","volume":"33","author":"YW Chen","year":"2022","unstructured":"Chen YW, Yang M, Wang MX, Jiang JH, Jiang DY, Chen ZL, et al. Refractory hypokalemia caused by cetuximab with advanced colorectal cancer patients: the case series and literature review. Anticancer Drugs. 2022;33:e789\u201394. https:\/\/doi.org\/10.1097\/CAD.0000000000001212.","journal-title":"Anticancer Drugs"},{"key":"465_CR14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/000313480407000204","volume":"70","author":"EA Mittendorf","year":"2004","unstructured":"Mittendorf EA, Merlino JI, McHenry CR. Post-parathyroidectomy hypocalcemia: incidence, risk factors, and management. Am Surg. 2004;70:114\u20139 discussion 119-20.","journal-title":"Am Surg."},{"key":"465_CR15","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1210\/jc.2012-1170","volume":"97","author":"OE Anastasiou","year":"2012","unstructured":"Anastasiou OE, Yavropoulou MP, Papavramidis TS, Tzouvara C, Triantafyllopoulou K, Papavramidis S, et al. Secretory capacity of the parathyroid glands after total thyroidectomy in normocalcemic subjects. J Clin Endocrinol Metab. 2012;97:2341\u20136. https:\/\/doi.org\/10.1210\/jc.2012-1170.","journal-title":"J Clin Endocrinol Metab"},{"key":"465_CR16","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s12020-020-02324-2","volume":"69","author":"J Pepe","year":"2020","unstructured":"Pepe J, Colangelo L, Biamonte F, Sonato C, Danese VC, Cecchetti V, et al. Diagnosis and management of hypocalcemia. Endocrine. 2020;69:485\u201395. https:\/\/doi.org\/10.1007\/s12020-020-02324-2.","journal-title":"Endocrine"},{"key":"465_CR17","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1089\/thy.2017.0309","volume":"28","author":"LA Orloff","year":"2018","unstructured":"Orloff LA, Wiseman SM, Bernet VJ, Fahey TJ 3rd, Shaha AR, Shindo ML, et al. American Thyroid Association Statement on Postoperative Hypoparathyroidism: Diagnosis, Prevention, and Management in Adults. Thyroid. 2018;28:830\u201341. https:\/\/doi.org\/10.1089\/thy.2017.0309.","journal-title":"Thyroid"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00465-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-025-00465-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00465-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T21:13:39Z","timestamp":1751663619000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-025-00465-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["465"],"URL":"https:\/\/doi.org\/10.1186\/s40780-025-00465-y","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with the Declaration of Helsinki. Written informed consent was obtained from the patient to publish the details of the medical case. Case reports were exempted from ethics approval at the Hokkaido University Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}